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Abstract
Study design Secondary analysis of a clinical trial.
Objectives To analyze adherence to 1-year transcranial Direct Current Stimulation (tDCS) clinical trial in people with
chronic pain due to spinal cord injury (SCI). We also explore the association between dropout and several baseline variables
such as age, depression levels, pain severity, number of days with pain in the last 7 days, walking ability, sleep, work,
relationship with others, and enjoyment with life.
Setting Boston, USA.
Methods Forty-six participants were enrolled in this trial, and 33 participants were randomized to receive either active or
sham tDCS.
Results Using the full intention-to-treat (ITT) criteria, only 8 participants (24%) finished the study. The median time to
dropout was seven (IQR:6,19) sessions (i.e., immediately after the first follow-up), regardless of the type of stimulation that
participants received (active vs. sham tDCS) (χ2= 0.025, p= 0.875). An exploratory analysis suggested that only the
number of days with pain in the last 7 days was moderately associated with dropout, with people experiencing less pain
being more prone to dropout from the study.
Conclusions Despite all the measures to improve study adherence (such as providing parking, flexibility to schedule
sessions, follow-up with participants by phone), it seems that long follow-up periods may increase the likelihood of dropout.
Given the need to understand long-term effects of interventions, longitudinal trials need to consider alternative designs or
methods of treatment (for instance home treatment or home assessment) to decrease attrition rate.
Introduction
People with spinal cord injury (SCI) frequently report
chronic neuropathic pain that is often refractory to medi-
cations [1, 2]. The development of novel pain therapeutic
approaches in the field of SCI research is a priority as laid
down by a joint position statement of the US Institutes of
Medicine and the National Academy of Sciences. Thus,
non-pharmacological interventions such as transcranial
Direct Current Stimulation (tDCS) can be helpful for
reducing neuropathic pain due to SCI.
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The number of clinical studies using tDCS has steadily
increased in the last years due to its promising clinical
results, safety profile, low cost, and relatively easy to use.
When applied for sufficient duration, tDCS alters the level
of cortical excitability and modulates the firing rate of
individual neurons, during and beyond the period of sti-
mulation [3].
Substantial previous research has shown that anodal
tDCS over the primary motor cortex (M1) can induce
clinically significant pain relief in chronic pain syndromes
[4–6] that outlast the stimulation period for several weeks
[7–9], with mild or absent side effects [10]. However, these
clinical trials often require large sample sizes, strict inclu-
sion, and exclusion criteria, and require multiple study
visits per trial. In fact, it has been shown recently that the
response to tDCS in fibromyalgia was achieved in 50% of
participants only after 15 sessions [11]. In fact, in our
study, in which we tested the effects of M1 tDCS
in participants with neuropathic pain following SCI, we
showed that a delayed treatment response at 1-week
follow-up (after 5 consecutive days of stimulation—
phase 1) and 4-weeks delayed response after additional
15 days of stimulation (phase 2) [12]. Therefore, the need to
have longer periods of treatment together with limitation of
transportation of people with SCI pose several potential
problems to subject retention, a challenge reflected in trial
dropout rates.
Indeed, reasons for dropouts are treatment related; either
because the participants were randomized to the active
treatment group and experienced adverse side effects, or to
the control group and experienced lack of efficacy [13].
Since two meta-analysis have shown significantly higher
dropout rates in the placebo arm as compared to the active
arm [14], and adverse effects are associated also with
increased dropout from a study, here we are interested in
analyzing the data comparing active vs. sham groups.
Therefore, in this article, we present adherence data, such
as time for dropout, from one longitudinal clinical trial that
was designed to assess the efficacy of repetitive sessions of
active vs. sham tDCS on pain relief in participant with
chronic neuropathic pain secondary to SCI [12]. Since
meta-analysis have shown significantly higher dropout rates
in the placebo arm as compared to the active arm [14], here
we are interested in analysing the data in an exploratory
manner comparing active vs. sham group.
Moreover, this specific population may have some spe-
cific challenges for adherence; for instance, some char-
acteristics such as severity of lesion (that would result in
additional transportation difficulties) may be associated
with dropout rates. Thus, in this trial, we further explore this
issue, by testing the association between several baseline
characteristics such as age, depression levels, pain severity,
number of days with pain in the last 7 days, walking ability,
sleep, work, relationship with others and enjoyment with
life with participant´s propensity to dropout from the trial.
Methods
The data presented in this study is the adherence of people
with SCI to a long-term clinical trial (SCIMS trial; clin-
icalTrials.gov Identifier: NCT01599767), which primary
objective was to assess the efficacy of tDCS on pain relief.
For more details about the effectiveness of tDCS on pain
relief please see Thibaut et al. [12].
Participants
Forty-six participants (10 females) with SCI (based on the
American Spinal Injury Association—ASIA—Impairment
Scale performed at time of enrollment) with a mean age of
48 (12.88) with moderate to severe sublesional chronic pain
(average Visual Analog Scale (VAS) score of 4 or greater)
and time (in years) since injury 6(±6.27)), with self-reported
pain since injury, were enrolled for the SCIMS trial
(inclusion criteria). From those, 33 participants were
randomized to receive either active (n= 16) or sham tDCS
(n= 17).
The exclusion criteria in the study were: active alcohol or
drug dependence; history of bipolar disorder or psychosis;
inability to travel to the study site; current use of any of the
following anti-epileptic medications or dopaminergic med-
ications known to reduce or inhibit the benefits of tDCS
treatment: carbamazepine, oxcarbazepine, phenytoin, ropi-
nirole (Requip), pramipexole (Mirapex), and cabergoline
(Dostinex); the following contradictions to tDCS: implanted
metal plates in the head, or deep brain stimulator (spinal
cord implants, including baclofen pumps, are not a contra-
indication as cranial currents do not reach the spinal cord).
Pregnancy at time of enrollment; and current use of
ventilator.
All participants provided written informed consent at
enrollment and the study was conducted according to the
declaration of Helsinki.
Study design
The complete SCIMS trial involves a total of 21 visits.
These visits include, one baseline assessment, 15 daily
sessions of tDCS and five follow-up assessments. Of these
21 visits, 4 of the follow-up assessments can be done over
the phone, whereas the other 17 visits require the subject to
physically travel to the research facility. However, as the
duration of this study is quite long (approx. 6 months), the
study is divided into two phases, in which the subject is
required to consent twice. The first consent is for phase I
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(visits 1–8) and if participants wish to continue (and con-
tinue to meet eligibility), they may consent for phase II
(visits 9–21) (Fig. 1). After a screening assessment to
evaluate eligibility for participation, baseline assessments
are performed, and participants then undergo five con-
secutive days of tDCS, with a follow-up at least 1-week
post-stimulation. After completion of this first phase, par-
ticipants have another follow-up visit at least 3 months after
the 1-week follow-up. This follow-up visit assesses pain as
well as other study measures (such as quality of life and
mood). If the subject wishes to continue further into the trial
and remains eligible, he/she then consents to the second part
of the trial (phase II).
During phase II of the trial, participants received 2-weeks
of the tDCS, and are asked to complete three additional
follow-up assessment visits (2 weeks, 4 weeks, and 8 weeks
after their final tDCS session). These three assessments can
be done in person, by mail or by phone. All tDCS sessions
were performed using the same parameters as in previous
studies e.g., ref. [15]. Each stimulation visit lasts about 30
min (20 min of tDCS) and assessment visits may vary from
approximately 1–1.5 h.
All enrolled participants were compensated for their time
and transportation costs when necessary.
Statistical analysis
The main objective of the present work was to test if there
were differences in term of dropout rate between active and
sham tDCS. For that purpose, Kaplan–Meier survival esti-
mates were generated to show the study adherence rates of
the two treatment groups (active vs. sham tDCS) throughout
the study visits for each respective study. Moreover, the
log-rank test was used to evaluate the equality of the sur-
vival distributions when comparing the two groups (active
and sham tDCS).
The secondary objective was to assess if there were some
participant´s characteristics that may be associated with
their propensity for dropping out from the study. Thus,
point biserial correlations were performed in order to assess
the potential relationship between dropout and several
Fig. 1 Study design. Phase 1, from Pre-screening (Visit 0) to follow-up (visit 8); and Phase II, from 6th tDCS session (Visit 9) to follow-up
(Visit 21)
Fig. 2 Participant adherence rate of the SCIMS trial—cumulative
retention distributions. tDCS visits are highlighted in gray
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baseline variables such as age, depression levels, pain
severity, number of days with pain in the last 7 days,
walking ability, sleep, work, relationship with others and
enjoyment with life.
In order to assess if there were side effect differences
that could explain the dropout rates, Chi-squares
tests were performed for each side effect variable in
order to assess differences across groups. Fischerʼs exact
tests were performed for groups with less than five
observations.
Results
The median survival until dropout for both groups was 7
(IQR: 6–19) sessions (that indicated the first follow-up).
There were no significant differences between the groups
(active vs. sham tDCS) in terms of time to dropout (χ 2(1)
= 0.025, p= 0.88) (Fig. 2).
We performed an additional analysis to assess if certain
baseline variables were associated with dropout. Therefore,
we assessed if age, depression levels, pain severity, number
of days with pain in the last 7 days, walking ability, sleep,
work, relationship with others, and enjoyment with life were
associated with dropout. Only the number of days with pain
in the last 7 days was moderately associated with dropout,
with people experiencing less pain more prone to dropout
from the study (rpb= -0.46).
tDCS side effects
Additional analyses were performed to test possible side
effects of tDCS on both groups, active vs. sham group.
Significant differences were found across groups for side
effects of scalp pain (p= 0.036), scalp burning sensation
(p= 0.006), tingling (p < 0.001), skin redness (p < 0.001),
and sleepiness (p < 0.001) (Table 1).
Discussion
This study assessed participants’ retention over a long-
itudinal tDCS clinical trial for pain relief in a cohort of 46
people with SCI.
Overall, the results show that there are no significant
differences between active and sham tDCS groups in terms
of time to dropout. These results differ from what was
previously reported in past trials, namely in meta-analysis
that showed that the dropout rates in the placebo arm were
significantly higher than the active arm [14]. Moreover, a
recent meta-analysis assessing the dropout rate in anti-
depressant studies using placebo or active comparator,
suggested that the dropout rate in the placebo arm was
strongly associated with the lack of efficacy [16], despite no
significant difference dropout rate between active (24.3 ±
8.27) vs. placebo (24.0 ± 9.04%) for the trials conducted in
the last decade. The reason for the differences here may also
be because of better placebo methods for tDCS, which
seems to be less guessed as active when compared with
drugs [17]. Nonetheless, it is important to highlight that the
sample size of the present study was rather small, and as
such the lack of a significant difference in terms of adher-
ence to active or sham tDCS needs to be confirmed by
larger trials as this may be a type II error.
In the present trial, only 8 (out of 33) participants com-
pleted the trial, which translates to a dropout rate of 76%. A
recent 16-week long duration trial assessing the effective-
ness of physical activity guidelines in patients with SCI,
showed a 18% dropout rate [18]. This rate was slightly
below the one found in other chronic pain trials, in which
dropout rates range from 20 to 50 % [13]. Moreover,
usually the reasons for dropouts are treatment related; either
because the participants were randomized to the active
treatment group and experienced adverse side effects, or to
the control group and experienced lack of efficacy [13].
Table 1 Side effects for each
group in the SCIMS trial
Sham (n= 17) Active (n= 16)
Side effect Absent Mild Moderate Severe Absent Mild Moderate Severe Significance
Headache 88.7 10.4 0.9 — 91.9 8.1 0 — >0.05
Neck pain 98.1 0.9 0.9 — 92.6 4.4 2.2 — >0.05
Scalp pain 99.1 0.9 — — 92.6 5.9 1.5 — 0.036*
Scalp burn sensation 100 — — — 91.9 5.1 2.9 — 0.006*
Tingling 56.1 41.1 1.9 0.9 34.6 50.7 14 0.7 <0.001*
Redness 83.2 15.9 0.9 — 56.7 41.1 2.2 — <0.001*
Sleepiness 83.2 15.9 0.9 — 56.7 41.1 2.2 — <0.001*
Concentration 99.1 0.9 — — 100 — — — >0.05
Mood 100 — — — 100 — — — >0.05
Values are expressed as a percentage. *Significant at p<0.05
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The results from this exploratory study show that tDCS
had a delayed pain decrease at 1-week follow-up
for phase 1 and only at 4-week follow-up for phase II [12].
This delayed response to intervention may potentially
explain the loss to follow-up in this trial, since
participants may perceived this intervention as not working
as expected or they believed they were receiving sham
tDCS.
Another important aspect to consider in this perceived
lack of efficacy is the definition of the maximum pain relief
that the intervention is able to induce, or simply what do
participants perceive as pain relief. A recent study with
chronic neuropathic pain following fibromyalgia suggested
that 15 sessions may be the median number of sessions
required in order to induce a significant clinical effect (i.e.,
50% pain reduction) [11]. Thus, it may be possible that five
consecutive sessions were not able to induce sufficient pain
relief in this population to be perceived as such up to that
point. This perceived lack of efficacy could potentially
explain the dropout of participants following the first round
of tDCS.
Another possibility for this high dropout rate could be
the potential side effects that arose from the intervention.
This has been already shown extensively in the literature, in
which increased dropout rate in drug trials is significantly
associated with adverse effect severity [19, 20]. This could
certainly be the case in this study, as participants with SCI
submitted to verum stimulation reported significant more
skin redness, sleepiness, scalp pain, scalp burning sensation,
and tingling as compared to those receiving the placebo.
However, when these side effects were reported, most of
them were of mild severity—which is consistent with pre-
vious reports in the literature [21]. Thus, side effects do not
seem to have influenced adherence in the present trial.
Moreover, the difference in terms of absolute dropout rate
between groups is inferior to 15%, which suggests a low
risk of intervention induced bias. It has also been suggested
that trial design, type of intervention, geographic area, or
culture can contribute for participants’ dropout rate [14].
Mobility difficulties may also have impacted the adherence
of these participants to the clinical trial. In fact, a multi-
centre trial with people with SCI demonstrated an inverse
relationship between mobility and pain scores, i.e., people
with moderate to high levels of mobility reported less pain
[22]. Moreover, people with chronic pain and SCI have
high susceptibility to stress and depression [23, 24], which
can seriously affect their adherence to time demanding
clinical trials. All of these factors may increase burden to
participants, and thus contribute to study dropout. Indeed,
adherence in this specific population may be predicted more
by burden related to research procedures (i.e., visits and/or
travel) than by efficacy of treatment. For instance, a pre-
vious trial showed that repeated administration of
onabotulinumtoxinA detrusor injections every 6 months
improved their incontinence problems, but despite that, only
20% of patients continued the repeated treatment [25].
In the present study, there were no differences between
active and sham tDCS in terms of participants’ propensity
to dropout, but there was an overall high dropout rate.
Therefore, we performed additional analysis to assess if
certain baseline variables, such as age, depression levels,
pain severity, number of days with pain in the last 7 days,
walking ability, sleep, work, relationship with others and
enjoyment with life, were associated with dropout. Results
show that only the number of days with pain in the last
7 days was moderately associated with dropout, with people
experiencing less pain being more prone to dropout from
the study. This is an interesting result, as it seems that pain
severity or level of pain seem to affect study adherence. On
the other hand, as shown before higher pain at baseline may
indicate more refractoriness to tDCS [15]. Future studies
should take this in consideration when determining study
population, as it seems that people with higher levels of
pain are more motivated to travel to the research facility for
multiple tDCS sessions.
For those reasons, it is important to offer to these parti-
cipants, new options such as the possibility of participating
in the stimulation and assessment sessions at home with
remote assistance from the clinical and research setting.
Therefore, the development of home-based protocols can be
very useful in order to overcome this difficulty trial com-
pliance [26].
Another interesting result in this trial is that, participants
tend to dropout from the study after the screening assess-
ment, prior to actual study commencement, as loss to
follow-up slope is greater at that point (see Fig. 1). So, in
the absence of perceived early benefits from the interven-
tion, adherence may be suboptimal. Once participants
actually start the stimulation, most participants do not
dropout until completion of the stimulation sessions. The
dropout rates increase again during the follow-up assess-
ment visits. One possibility is that the one that feel greater
pain, are also the ones more motivated to be complete the
stimulation sessions because of the potential clinical bene-
fits. As soon as therapy ends, then they are less likely to
adhere to the assessments that will not be perceived as
having any clinical benefit.
This loss to follow-up has been reported in many other
clinical trials [27, 28], and poses serious threats to the
validity of the study by potentially introducing bias to the
results, as participants that dropout may have distinct
characteristics from those that do not dropout [29]. Again, it
is not possible to disentangle if this high dropout rate was
due to lack of perceived efficacy of the tDCS intervention.
If the pain levels were low enough for them to dropout from
the study, or even if in low levels of pain there is no actual
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benefit from the tDCS intervention or in the case there is,
the effects are not perceived as beneficial.
It is important to highlight that in the SCIMS trial,
participants were given the opportunity to perform
follow-up assessments over the phone. Despite that, there
was a significant loss to follow-up, starting at 1 month
after tDCS has ended. It is possible that the elapsed
time between the stimulation and the follow-up
assessments negatively impacted participants’ motivation
to continue in the trial. Moreover, it is possible that the
intervention´s perceived lack of efficacy increased
over time, as the perceived potential benefits were
becoming smaller. Additionally, participants may have felt
more motivated to receive the intervention rather than
complete the long follow-up assessments (with a 1-hour
burden).
This study is one of the first studies testing the effec-
tiveness of tDCS for chronic neuropathic pain in people
with SCI with long follow-ups (that showed to be important
given our efficacy results please see ref. [12]. And as such, a
placebo intervention (i.e., sham tDCS) was chosen as
comparator in order to increase the validity of the results,
especially due to the 15 sessions timeframe that has been
shown to induce a clinical meaningful effect in terms of
pain relief. Thus, in this sense, it was important to maintain
the comparator across the 15 sessions. If there seem to be no
differences in terms of dropout rates due to comparator, the
available data suggest that, future longitudinal tDCS clinical
trials with participants with SCI, may benefit from changes
in the study design. First of all, patients with refractory pain
may be more prone to adhere to the study. Second, at early
stages of the intervention adherence may be improved by
facilitating the commute to the research facility. But if these
trials require larger time commitments, a stepped home
intervention may be more beneficial (see Fig. 1). Addi-
tionally, one limitation of this study was that subjects were
randomized upon consenting, and that may have produced a
minor imbalance in groups prior to the start of stimulation.
Therefore, future studies should only perform subject´s
randomization subjects immediately before the first stimu-
lation session.
Conclusion and future directions
This work provides insights about the participants’ adher-
ence to long-term clinical trials assessing the effect of tDCS
for pain relief. Despite the safety profile of tDCS and the
absent difference in terms of dropout rate between active
and sham tDCS groups, long-term clinical trials remain a
challenge for research participants. Specific populations
may be more vulnerable for this long-term adherence
commitment than others, especially those with lower levels
of pain. Special attention must be given to long-term fol-
low-ups, especially those that involve a significant time
burden for participants. Trials should be designed in order
to include specific strategies that aim to increase compliance
in different phases of the clinical trial. These patient-
directed strategies to improve compliance may include
education about the relevance of the clinical trial and about
her/his adherence to all regimens (including assessments).
Some recommendations to improve adherence are sum-
marized in Table 2.
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Table 2 Recommendations for future longitudinal clinical trials with
tDCS for Chronic Pain with people with spinal cord injury
Recommendations for future longitudinal clinical trials with tDCS
for SCI
Participant-centered:
Participants with lower levels of pain may be more vulnerable to
dropout in long-term clinical trials:
Participants with resistant pain may be more motivated to
complete the trial
Motivation to participate in the trial needs to be closely
monitored in the different phases of the trial, especially during
assessments
Difficulties with mobility may impact adherence
For short-term trials, improving commuting to the research
facility may be helpful
For long-term trials, home-based intervention options may be
considered, thus reducing the impact on their lives
Participants-directed strategies to improve compliance may include
education about the relevance of the clinical trial and about her/his
adherence to all regimens (including assessments).
Research team-centered:
Trials should be designed in order to include specific strategies that
aim to increase compliance in different phases of the clinical trial:
Well-prepared research team
Good communication skills
Welcoming behavior with participants
Providing flexible or expanded clinic hours.
Uncertain benefits and potential risks associated with participation
can impact compliance. This should be discussed and monitored
with participants.
Family and friends centered:
Involving family and friends in the treatment may also have a
positive impact on compliance by increasing the social support to
the subject. Depending on specific personal characteristics and
needs of the participant, family and friends can be involved in order
to support the subject during his/her participation.
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